Scholarlink

<p>Symptomatic adenomyosis is a known impediment to successful implantation and pregnancy in in vitro fertilization; yet optimal pre-treatment strategic approach remains uncertain. This randomized controlled trial compared the effects of low dose letrozole (2.5&#xa0;mg, thrice weekly for three-months) and GnRH agonist (3.6&#xa0;mg/month for three-months) on implantation markers and reproductive outcomes in 156 women with symptomatic diffuse adenomyosis undergoing frozen embryo transfer. Seventy-five women with tubal factor infertility served as controls. Endometrial biopsies during the implantation window were analyzed pre- and post-treatment for key receptivity markers via immunohistochemistry and ELISA. Women with adenomyosis exhibited higher BMI (<i>p</i> = 0.02) and basal estradiol (<i>p</i> = 0.03) than controls. No significant differences in clinical pregnancy (letrozole: 27.9%, GnRHa: 29.9%), live birth (letrozole: 17.7%, GnRHa: 19.5%), and miscarriage rates (letrozole: 22.7%, GnRHa: 21.7%) were observed between treatment groups. Notably, outer myometrial involvement was linked to higher odds of pregnancy outcome (OR 3.26, <i>p</i> = 0.01). Both treatment arms showed improved endometrial expression of PR and integrin αvβ3 (<i>p</i> &lt; 0.01), along with significant downregulation (<i>p</i> &lt; 0.001) of ERα, ERβ, VEGF, and eNOS, suggesting enhanced receptivity. These findings suggest that low dose letrozole may be a viable alternative to GnRHa, with lesion location serving as a critical determinant of reproductive success in adenomyosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative analysis of low-dose letrozole versus GnRH agonist on implantation markers and IVF outcomes in symptomatic adenomyosis: a randomized trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月31日

查看全文
  • Sunita Sharma,
  • Sourav RoyChoudhury,
  • Pratip Chakraborty,
  • Pranab Paladhi,
  • Kishan Shaw,
  • Meenakshi Karan,
  • Shubhendu Hazra,
  • Subhra Prakash Hui,
  • Ratna Chattopadhyay,
  • Arup Kumar Majhi

摘要

Symptomatic adenomyosis is a known impediment to successful implantation and pregnancy in in vitro fertilization; yet optimal pre-treatment strategic approach remains uncertain. This randomized controlled trial compared the effects of low dose letrozole (2.5 mg, thrice weekly for three-months) and GnRH agonist (3.6 mg/month for three-months) on implantation markers and reproductive outcomes in 156 women with symptomatic diffuse adenomyosis undergoing frozen embryo transfer. Seventy-five women with tubal factor infertility served as controls. Endometrial biopsies during the implantation window were analyzed pre- and post-treatment for key receptivity markers via immunohistochemistry and ELISA. Women with adenomyosis exhibited higher BMI (p = 0.02) and basal estradiol (p = 0.03) than controls. No significant differences in clinical pregnancy (letrozole: 27.9%, GnRHa: 29.9%), live birth (letrozole: 17.7%, GnRHa: 19.5%), and miscarriage rates (letrozole: 22.7%, GnRHa: 21.7%) were observed between treatment groups. Notably, outer myometrial involvement was linked to higher odds of pregnancy outcome (OR 3.26, p = 0.01). Both treatment arms showed improved endometrial expression of PR and integrin αvβ3 (p < 0.01), along with significant downregulation (p < 0.001) of ERα, ERβ, VEGF, and eNOS, suggesting enhanced receptivity. These findings suggest that low dose letrozole may be a viable alternative to GnRHa, with lesion location serving as a critical determinant of reproductive success in adenomyosis.